The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

16 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines.EBI
Glaxosmithkline
Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity.EBI
University Of Bath
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.EBI
Health & Science University
Development and structural analysis of adenosine site binding tankyrase inhibitors.EBI
University Of Oulu
Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.EBI
University Of Oulu
Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.EBI
Irbm/Merck Research Laboratories
Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).EBI
Irbm-Merck Research Laboratories Rome
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-EBI
Astrazeneca
Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules.EBI
University Of Perugia
Potent 2,3-dihydrophthalazine-1,4-dione derivatives as dual inhibitors for mono-ADP-ribosyltransferases PARP10 and PARP15.EBI
University Of Perugia
Rational design of selective inhibitors of PARP4.EBI
Initial Therapeutics
Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II.EBI
Symeres
Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor.EBI
University Of Oslo
Rational Design of Cell-Active Inhibitors of PARP10.EBI
Oregon Health And Science University
4-(Phenoxy) and 4-(benzyloxy)benzamides as potent and selective inhibitors of mono-ADP-ribosyltransferase PARP10/ARTD10.EBI
University Of Oulu
Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.EBI
Leibniz-Forschungsinstitut F�R Molekulare Pharmakologie (Fmp)